Skip to Main Content

Paper Details

Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells.
Sci Rep
1
2022
AKT, AToMI, CEP-701, K252a, PDK1, PDK4, PP2A, UCN-01, cancer, glioblastoma, glioblastoma cells, heterogeneous, mitochondrial pyruvate dehydrogenase kinase, protein phosphatase 2A, pyruvate, staurosporine, staurosporines
Author NameAffiliation
Michael OhlmeyerIcahn School of Medicine at the Mount Sinai
Michael OhlmeyerAtux Iskay LLC
Michael OhlmeyerIcahn School of Medicine at the Mount Sinai
Michael OhlmeyerAtux Iskay LLC
Krister WennerbergInstitute for Molecular Medicine Finland, University of Helsinki
Krister WennerbergUniversity of Copenhagen
Tero AittokallioInstitute for Molecular Medicine Finland, University of Helsinki
Tero AittokallioUniversity of Oslo
Tero AittokallioInstitute for Cancer Research, Oslo University Hospital
  • 1 - 9

Datasets

Release 1.2